Log in Free sign up

Oncternal Therapeutics (ONCT) News and press releases

News

From Benzinga Pro

99 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company.

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Maxim Group Initiates Coverage On Oncternal Therapeutics with Buy Rating, Announces Price Target of $3.5

News, Price Target, Initiation, Analyst Ratings

Maxim Group analyst Naureen Quibria initiates coverage on Oncternal Therapeutics (NASDAQ:ONCT) with a Buy rating and announces Price Target of $3.5.

Oncternal Therapeutics Q1 EPS $(0.20), Inline

Oncternal Therapeutics (NASDAQ:ONCT) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 66.67 percent decrease over losses of $(0.12) per share from the same period last

Earnings Scheduled For May 5, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

Oncternal Therapeutics's Earnings Outlook

Oncternal Therapeutics (NASDAQ:ONCT) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Oncternal Therapeutics will report an earnings per share (EPS) of $-0.20.

66 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday.

12 Health Care Stocks Moving In Monday's Intraday Session

Intraday Update, Markets, Movers

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

Wednesday's session saw 784 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 431 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Tuesday, 242 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 466 companies hit new 52-week lows.

Oncternal Discontinues Enrollment In ONCT-216 Study For Soft Tissue Cancer

Biotech, News, Penny Stocks, Health Care, General

Oncternal Therapeutics Deprioritizes Development Of ONCT-216 To Focus Resources On Phase 3 Trial For Zilovertamab In Treatment Of Mantle Cell Lymphoma ; Discontinues Enrollment In Phase 1/2 Study Of ONCT-216

Biotech, News, FDA, General

Discontinued enrollment of Phase 1/2 trial of ONCT-216 in Ewing sarcoma Resources will be primarily reallocated to our zilovertamab global registrational Phase 3 study ZILO-301, which is expected to be

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Friday's morning session, 234 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 78 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 671 companies achieved new lows for the year.

Oncternal Therapeutics Q4 EPS $(0.16) Down From $(0.09) YoY, Sales $600.00K Down From $1.59M YoY

Oncternal Therapeutics (NASDAQ:ONCT) reported quarterly losses of $(0.16) per share. This is a 77.78 percent decrease over losses of $(0.09) per share from the same period last year. The company reported $600.00

Earnings Scheduled For March 10, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million.

Press releases

From Benzinga Pro

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results

Earnings, Press Releases

Global registrational Phase 3 study, ZILO-301, of zilovertamab in patients with MCL on track to be initiated in Q3 2022Presenting interim clinical data update from the ongoing Phase 1/2 clinical trial of zilovertamab in

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Health Care, Press Releases

SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results

News, Press Releases

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will

Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma

Discontinued enrollment of Phase 1/2 trial of ONCT-216 in Ewing sarcomaResources will be primarily reallocated to our zilovertamab global registrational Phase 3 study ZILO-301, which is expected to be initiated in Q3

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results

Earnings, Press Releases

Reached consensus with the FDA on the design and major details of the global Phase 3 Study ZILO-301 to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib, which is on track to be initiated in

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results

News, Press Releases

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

News, Financing, Press Releases

SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has